Researchers at BellBrook Labs have developed a high throughput screening (HTS) assay to discover small molecule modulators for the immunosuppressive ectonucleotidase, CD73. The Transcreener ADO CD73 Assay detects adenosine (ADO), the product of a CD73 reaction, allowing researchers to monitor CD73 activity with simple, mix-and-read fluorescent detection.
Also known as ecto-5’ nucleotidase or 5’-nucleotidase, CD73 is an anchored cell surface protein that plays a critical role in purinergic signaling by catalyzing the hydrolysis of AMP into adenosine and phosphate. Multiple lines of research have shown that adenosine is immunosuppressive in the tumor microenvironment, and ectonucleotidase enzymes have emerged as promising immuno-oncology targets.
The Transcreener CD73 Assay is a competitive immunoassay that uses a coupling enzyme to convert AMP to ADP, which is then detected by the proven Transcreener ADP² Assay. The assay is designed for HTS in miniaturized 384 or 1536 well formats. It provides a quantitative measurement of CD73 ...
